CASE REPORT
Dilated cardiomyopathy in the course of thrombophilia
 
More details
Hide details
1
Department of Internal Medicine, Medical University, Lublin, Poland
2
Student Scientific Society, Medical University, Lublin, Poland
CORRESPONDING AUTHOR
Andrzej Prystupa   

Department of Internal Medicine, Medical University, Lublin, Staszica 16, 20-081 Lublin, Poland.
 
J Pre Clin Clin Res. 2010;4(2):165–167
KEYWORDS
ABSTRACT
A 40-year-old patient with diagnosed thrombophilia was admitted to the Department due to symptoms suggestive of pulmonary embolism. The imaging results excluded pulmonary embolism; echocardiography revealed dilated cardiomyopathy. The report discusses the association between thrombophilia and possible development of cardiomyopathy.
 
REFERENCES (15)
1.
Dec GW, Fuster V: Idiopathic dilated cardiomyopathy. N Engl J Med 1994, 331, 1564-1575.
 
2.
Hershberger RE, Kushner JD, Parks SB: Dilated cardiomyopathy overview. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. Gene Reviews [Internet]. Seattle (WA): University of Washington, Seattle, 2008.
 
3.
Pankuweit S, Richter A, Ruppert V, Maisch B: Familial predisposition and microbial etiology in dilated cardiomyopathy. Herz 2009, 34, 110- 116.
 
4.
Ng T, Brown JR, Edmondson RA, Tillyer ML: Catastrophic arterial thromboembolism associated with factor V Leiden. Eur J Vasc Endovasc Surg 2000, 19, 551-553.
 
5.
Mandegar MH, Saidi B, Roshanali F: Extensive arterial thrombosis in a patient with factor V Leiden mutation. Interact Cardiovasc Thorac Surg 2010, 11, 127-129.
 
6.
Dönmez Y, Kanadasi M, Tanrıverdi K, Demir M, Demirtas M, Cayli M, Alhan C, Baslamisli F: Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 2004, 45, 505-512.
 
7.
Glueck CJ, Munjal J, Aregawi D, Agloria M, Winiarska M, Khalil Q, Wang P: Thrombophilia-hypofibrinolysis and atherothrombotic cardiovascular disease < or = age 45 years. Transl Res 2007, 150, 93-100.
 
8.
Bock S, Harris J, Balazs I, Trent J: Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Gene 1985, 39, 67-69.
 
9.
Lane D, Bayston T, Olds R, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J: Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997, 77, 197-211.
 
10.
Fujimori Y, Okimatsu H, Kashiwagi T, Sanda N, Okumura K, Takagi A, Nagata K, Murate T, Uchida A, Node K, Saito H, Kojima T: Molecular defects associated with antithrombin deficiency and dilated cardiomyopathy in a Japanese patient. Inter Med 2008, 47, 925-931.
 
11.
De Stafano V, Chiusolo P, Paciaroni K, Leone G: Epidemiology of factor V Leiden: clinical implications. Semin Hemostas 1998, 24, 367-379.
 
12.
Morton KE, Gavaghan TP, Krilis SA, Daggard GE, Baron DW, Hickie JB, Chesterman CN: Coronary artery bypass graft failure – an autoimmune phenomenon. Lancet 1987, 2, 977-978.
 
13.
Brown JH, Doherty CC, Allen DC, Morton P: Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus. Br Med J 1988, 296, 1505.
 
14.
Doggen CJM, Cats VM, Bertina RM, Rosendaal FR: Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin G20210A. Circulation 1998, 97, 1037-1041.
 
15.
Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ: Prevalence of factor V Leiden and prothrombin variant G20210A in patients age < 50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000, 36, 717-722.
 
eISSN:1898-7516
ISSN:1898-2395